NAMPT and metabolic dysfunction-associated steatotic liver disease: Future research is required in order to evaluate serum visfatin levels in the newly defined MAFLD using the new diagnosis criteria, as well as in patients with portal inflammation and NAFLD patients with concomitant atherosclerotic cardiovascular disease.